Shenzhen Drawray Biotech Co., Ltd. (hereinafter referred to as “Drawray”), established in 2019, is a high-tech enterprise in the in-vitro diagnostics (IVD) industry. We specialize in the R&D, production, sales, and service of innovative Point-of-Care Testing (POCT) products, providing advanced diagnostic solutions to enhance healthcare delivery worldwide.

Drawray utilizes three core IVD technology platforms—CLIA, FIA, and Rapid Test. Our product portfolio spans critical areas such as cardiac markers, thyroid function, autoimmunity, infectious diseases, reproductive health, and more.

Committed to excellence, we hold ISO 13485 and ISO 9001 certifications and have achieved over 179 CE certifications and more than 40 patents, demonstrating our dedication to continuous innovation.

Guided by our mission, "Technological innovation brings life care all around," and our vision to "become a global leader in rapid diagnostics," Drawray strives to enhance patient care, improve healthcare outcomes, and reduce costs. Through ongoing research and development, we aim to lead the industry with reliable and efficient diagnostic solutions.